Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1293296 | 0.84 | S1PR1 (0.71) | S1PR1S1PR3 | |
| SCHEMBL13020134 | 0.84 | S1PR1 (0.71) | S1PR1S1PR3 | |
| SCHEMBL12102355 | 0.84 | S1PR1 (0.52) | S1PR1S1PR3 | |
| SCHEMBL2606636 | 0.82 | S1PR1 (0.68) | S1PR1S1PR3 | |
| SCHEMBL1293465 | 0.81 | S1PR1 (0.59) | S1PR1S1PR3 | |
| SCHEMBL1293244 | 0.80 | RXRA (0.51) | S1PR1S1PR3 | |
| SCHEMBL2115564 | 0.80 | XDH (0.57) | S1PR1S1PR3 | |
| SCHEMBL3433651 | 0.78 | S1PR1 (0.66) | S1PR1S1PR3 | |
| SCHEMBL22816633 | 0.78 | S1PR1 (0.55) | S1PR1S1PR3 | |
| SCHEMBL1293435 | 0.78 | S1PR1 (0.55) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| EP-2443115-B1 | Pyrrolo-pyridine derivatives useful to treat diseases connected to S1P1 receptors | GLAXO GROUP LTD (GB) | 2013-08-28 | — | — | EP | disclosed |
| EP-2563785-A1 | COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS | Glaxo Group Limited (GB) | 2013-03-06 | — | — | EP | disclosed |
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| US-8389508-B2 | Heterocyclic compounds | GLAXO GROUP LIMITED (GB) | 2013-03-05 | — | — | US | disclosed |
| EP-2445891-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | Glaxo Group Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120101123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101086-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY S1P1 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2012-04-26 | — | — | US | disclosed |
| WO-2011134280-A1 | COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| WO-2011134280-A1 | COMPOUNDS AS AGONISTS OF S1P1 RECEPTORS | GLAXO GROUP LIMITED (GB) | 2011-11-03 | — | — | WO | disclosed |
| WO-2010148649-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010148649-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010145202-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010145202-A1 | THIAZOLE OR THIADIZALOE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE 1 (S1P1) RECEPTOR AGONISTS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010145201-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146104-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY SLPL RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146105-A1 | S1P1 AGONISTS COMPRISING A BICYCLIC N-CONTAINING RING | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
| WO-2010146104-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY SLPL RECEPTORS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101123-A1 | COMPOUNDS | CYP11B2, CYP11B1, GPR119 | S1PR1 1075/4885S1PR3 1079/4885 |
| US-20120101086-A1 | THIADIAZOLE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF DISORDERS MEDIATED BY S1P1 RECEPTORS | S1PR1, S1PR3, S1PR5 | S1PR1 1/4885S1PR3 2/4885 |
| US-20120101134-A1 | 5-MEMBERED HETEROARYL DERIVATIVES USED AS SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS | S1PR1, S1PR5, S1PR3 | S1PR1 1/4885S1PR3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.